OTLK - Outlook Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.0150 (-2.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.6800
Bid0.550 x 1400
Ask0.000 x 900
Day's Range0.6350 - 0.7300
52 Week Range0.2050 - 1.1000
Avg. Volume52,006
Market Cap59.434M
Beta (3Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-1.220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business partner and largest investor, receiving $4.0 million of cash proceeds in exchange for the issuance of 4,288,624 shares of common stock at $0.9327 per share.  The Company has received $16.0 million to date from the sale of its common stock to BioLexis under this private placement, which was previously announced on November 6, 2018.  The remaining $4.0 million will be funded on February 1, 2019, subject to achieving certain funding milestones as set forth in the purchase agreement. The Company intends to use the net proceeds from the private placement primarily for clinical trials for its lead product candidate, ONS-5010, and for working capital and general corporate purposes, including agreed repayments on its senior secured notes.

  • We're sorry this is all we were able to find about this topic.